


### AMENDMENTS TO THE CLAIMS

Please add or amend the claims to read as follows:

1. (Previously presented) A phosphatidylethanolamine conjugate according to the formula



wherein

R<sub>1</sub> is a linear, saturated, mono-unsaturated, or poly-unsaturated, alkyl chain ranging in length from 2 to 30 carbon atoms;

R<sub>2</sub> is a linear, saturated, mono-unsaturated, or poly-unsaturated, alkyl chain ranging in length from 2 to 30 carbon atoms;

Y is either nothing or a spacer group ranging in length from 2 to 30 atoms, wherein said spacer comprises —CO—alkylene—NH—, —CO—alkylene—CO— or a combination thereof; and

X is either a physiologically acceptable monomer, dimer, or oligomer, wherein n is unity, or a physiologically acceptable polymer, wherein n is a number from 1 to 1,000, wherein x is a glycosaminoglycan;

wherein if Y is nothing the phosphatidylethanolamine is directly linked to X via a carboxylic group.

2. (Previously presented) The compound according to claim 1, wherein the glycosaminoglycan is hyaluronic acid, heparin, heparan sulfate, chondroitin sulfate, keratin, keratan sulfate, dermatan sulfate or a derivative thereof.

APPLICANT(S): YEDGAR, Saul et al.  
SERIAL NO.: 09/756,765  
FILED: January 10, 2001  
Page 4

Attorney Docket No.: P-2507-US

3. (Previously presented) The compound according to claim 1, wherein the glycosaminoglycan is di- and trisaccharide unit monomers of glycosaminoglycans.

4. (Previously presented) The compound according to claim 3, wherein the chondroitin sulfate is chondroitin-6-sulfate, chondroitin-4-sulfate or a derivative thereof.

5. (New) The compound according to claim 1, wherein the glycosaminoglycan is hyaluronic acid.